Upgrade to SI Premium - Free Trial

Acadia Pharma (ACAD)

20.19 -0.25 (1.22%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/11/26)

Latest Headlines

Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026 October 21, 2026 4:05 PM - BizWire Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market October 21, 2026 10:40 AM - StreetInsider UBS Downgrades Acadia Pharmaceuticals (ACAD) to Neutral October 13, 2026 7:50 AM - StreetInsider Acadia Pharmaceuticals (ACAD) PT Lowered to $36 at RBC Capital October 8, 2026 8:26 AM - StreetInsider RBC Capital on Acadia Pharmaceuticals (ACAD): 'shares remain fundamentally undervalued' October 5, 2026 1:34 PM - StreetInsider Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041 September 28, 2026 4:05 PM - BizWire Acadia Pharmaceuticals (ACAD) PT Lowered to $33 at H.C. Wainwright September 28, 2026 6:55 AM - StreetInsider Increasing unusual option volume: GENI ACAD BUG XEL LESL GFL AKAM NKTR BURL QFIN September 25, 2026 10:03 AM - StreetInsider Acadia Pharmaceuticals (ACAD) PT Lowered to $35 at Needham September 25, 2026 7:06 AM - StreetInsider Acadia Pharmaceuticals (ACAD) PT Lowered to $33 at Citizens on Ph2 Miss for Remlifanserin September 25, 2026 4:11 AM - StreetInsider Form 8-K ACADIA PHARMACEUTICALS For: Sep 24 September 24, 2026 5:11 PM - SEC Filing Goldman Sachs Reiterates Sell Rating on Acadia Pharmaceuticals (ACAD) September 24, 2026 1:41 PM - StreetInsider TD Cowen Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD) September 24, 2026 12:20 PM - StreetInsider Citi cuts Acadia Pharmaceuticals price target to $33 September 24, 2026 12:18 PM - StreetInsider Acadia Pharmaceuticals (ACAD) PT Lowered to $34 at BMO Capital Amid Heavy Selling September 24, 2026 12:16 PM - StreetInsider Acadia Pharmaceuticals drops on trial miss September 24, 2026 10:02 AM - StreetInsider Acadia's Alzheimer's drug narrowly misses Phase 2 primary endpoint September 24, 2026 7:00 AM - StreetInsider Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP) September 24, 2026 7:00 AM - BizWire Oppenheimer Reiterates Perform Rating on Acadia Pharmaceuticals (ACAD) September 23, 2026 5:24 AM - StreetInsider Increasing unusual option volume: UTHR ABUS OPRA GFL ACAD September 21, 2026 6:03 AM - StreetInsider Increasing unusual option volume: ACAD ALHC PLAY FPS ITUB NAVN WVE UAL XEL September 15, 2026 10:01 AM - StreetInsider Form 8-K ACADIA PHARMACEUTICALS For: Sep 11 September 11, 2026 5:15 PM - SEC Filing Canaccord Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD) September 3, 2026 6:44 AM - StreetInsider Acadia Pharmaceuticals (ACAD) PT Raised to $28 at Morgan Stanley August 25, 2026 8:30 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD) August 25, 2026 6:57 AM - StreetInsider Acadia Pharmaceuticals (ACAD) PT Raised to $40 at Citi August 25, 2026 5:02 AM - StreetInsider EU approves Acadia's trofinetide for Rett syndrome treatment August 24, 2026 6:10 AM - StreetInsider European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union August 24, 2026 3:01 AM - BizWire Acadia Pharmaceuticals (ACAD) PT Raised to $49 at UBS August 17, 2026 6:50 AM - StreetInsider Canaccord Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD) August 13, 2026 6:48 AM - StreetInsider Acadia Pharmaceuticals (ACAD) PT Raised to $27 at Morgan Stanley August 10, 2026 8:35 AM - StreetInsider Form 4 ACADIA PHARMACEUTICALS For: Aug 05 Filed by: Schneyer Mark C. August 7, 2026 6:00 PM - SEC Filing Form SCHEDULE 13G ACADIA PHARMACEUTICALS Filed by: STATE STREET CORP August 7, 2026 8:21 AM - SEC Filing H.C. Wainwright Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD) August 6, 2026 6:56 AM - StreetInsider Form 144 ACADIA PHARMACEUTICALS Filed by: Schneyer Mark C. August 5, 2026 4:50 PM - SEC Filing Acadia Pharmaceuticals (ACAD) PT Raised to $37 at RBC Capital on 'Strong Sales' August 5, 2026 7:44 AM - StreetInsider Acadia Pharmaceuticals (ACAD) PT Raised to $25 at Oppenheimer August 5, 2026 6:33 AM - StreetInsider Form 10-Q ACADIA PHARMACEUTICALS For: Jun 30 August 5, 2026 6:02 AM - SEC Filing Acadia Pharmaceuticals (ACAD) PT Raised to $36 at Citizens: Remains a Top Pick August 5, 2026 4:07 AM - StreetInsider Acadia Pharma (ACAD) Tops Q2 EPS by 12c ; Offers Guidance August 5, 2026 12:52 AM - StreetInsider Form 8-K ACADIA PHARMACEUTICALS For: Aug 04 August 4, 2026 4:18 PM - SEC Filing Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results August 4, 2026 4:05 PM - BizWire Form 4 ACADIA PHARMACEUTICALS For: Jul 29 Filed by: Thompson Elizabeth H.Z. July 31, 2026 6:00 PM - SEC Filing Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference July 30, 2026 5:57 PM - BizWire Acadia Pharmaceuticals (ACAD) PT Raised to $14.50 at BofA Securities July 29, 2026 5:19 AM - StreetInsider Full Article List